Patients treated with trastuzumab deruxtecan + pertuzumab had a statistically significant and clinically meaningful improvement in PFS compared with standard of care. Topline results were ...

Trastuzumab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent ...

At seven-years follow up, invasive disease-free survival was 80.8% with adjuvant T-DM1 and 67.1% with adjuvant trastuzumab alone. Overall survival was 89.1% with T-DM1 and 84.4% with trastuzumab ...

Researchers found no significant differences in safety outcomes between trastuzumab biosimilars and the originator product across subgroups. Trastuzumab biosimilars have similar safety profiles as ...

A regulatory decision is expected during the first quarter of 2025. The Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application (sBLA) for ...

Sixty-three patients were enrolled in the phase 2 IMMUN-HER study (NCT03144947) evaluating SC (n = 32) vs IV (n = 31) trastuzumab administration. In the IV trastuzumab arm, 20 of 31 patients (64.5 ...

The National Institute for Health and Care Excellence (NICE) has not recommended trastuzumab deruxtecan for people with HER2-low breast cancer. It says that although it would be a "potentially ...

Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults. Next review: More ...

SAN ANTONIO — Fam-trastuzumab deruxtecan-nxki improved outcomes compared with capecitabine-based regimens as third-line treatment for certain patients with HER2-positive metastatic breast cancer ...

At the 2022 ASCO Annual meeting, trastuzumab dreuxtecan was found to be a superior standard of care therapy for patients with hER2-low, hormone-positive metastatic breast cancer. “Trastuzumab ...